Lucid Diagnostics (NASDAQ:LUCD) Announces Earnings Results

Lucid Diagnostics (NASDAQ:LUCD) released its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06), FiscalAI reports. The firm had revenue of $1.47 million during the quarter, compared to the consensus estimate of $1.43 million.

Here are the key takeaways from Lucid Diagnostics’ conference call:

• Commercial coverage milestone: Laboratory benefit manager Concert issued a positive EsoGuard coverage policy, and three client health plans have adopted it, representing access to nearly 10 million covered lives. Lucid expects additional plans to follow and believes the policy may help establish a precedent with other payers.
• Medicare and VA progress: Lucid continues to expect a positive Medicare draft LCD, although CMS and its contractors face a broad backlog. VA contracting is progressing, with contracts expected to contribute more meaningfully after the federal fiscal year begins October 1.
• Commercialization infrastructure expanding: Preliminary results from Lucid’s cost-effectiveness model reportedly show EsoGuard is cost-effective across most modeled scenarios, while health-system implementations, EHR integration, and physician-focused sales efforts are advancing.
• Testing volume remained constrained: Lucid performed 2,770 tests in the second quarter, within its target range of 2,500 to 3,000, and recognized $1.5 million of revenue. The company is deliberately shifting volume toward contracted, VA, and commercial opportunities that are more likely to generate payment rather than simply increasing total tests.
• Reimbursement and cash-burn risks remain: Only about 28% of adjudicated second-quarter claims produced an allowable amount, with denials often tied to medical-necessity, prior-authorization, or documentation requirements. Cash was $33.4 million at quarter-end, while the trailing four-quarter average cash burn was $11.6 million per quarter, leaving Medicare and improved commercial collections critical to reducing future funding needs.

Lucid Diagnostics Stock Performance

Shares of NASDAQ LUCD traded up $0.00 during trading on Friday, hitting $0.97. 574,529 shares of the company were exchanged, compared to its average volume of 1,252,030. The company has a fifty day moving average price of $0.99 and a 200-day moving average price of $1.13. Lucid Diagnostics has a 12-month low of $0.86 and a 12-month high of $1.63. The firm has a market capitalization of $196.68 million, a PE ratio of -2.06 and a beta of 1.08.

Analyst Upgrades and Downgrades

LUCD has been the subject of a number of analyst reports. Ascendiant Capital Markets upped their target price on Lucid Diagnostics from $9.00 to $9.25 and gave the stock a “buy” rating in a report on Monday, June 8th. Maxim Group lowered their price objective on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Weiss Ratings upgraded Lucid Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 4th. BTIG Research reaffirmed a “buy” rating and issued a $2.50 price target on shares of Lucid Diagnostics in a report on Friday, May 15th. Finally, Wall Street Zen lowered shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $4.19.

Insider Buying and Selling

In other Lucid Diagnostics news, Director Dennis Matheis acquired 245,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $1.00 per share, for a total transaction of $245,000.00. Following the completion of the acquisition, the director owned 1,033,443 shares of the company’s stock, valued at approximately $1,033,443. The trade was a 31.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Lucid Diagnostics

Institutional investors have recently made changes to their positions in the stock. Two Seas Capital LP purchased a new stake in Lucid Diagnostics in the third quarter valued at approximately $3,030,000. Geode Capital Management LLC raised its stake in Lucid Diagnostics by 420.3% in the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after buying an additional 1,274,194 shares in the last quarter. Masters Capital Management LLC raised its position in shares of Lucid Diagnostics by 46.6% during the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after acquiring an additional 1,272,000 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in Lucid Diagnostics by 87.3% during the third quarter. Alyeska Investment Group L.P. now owns 1,383,116 shares of the company’s stock worth $1,397,000 after purchasing an additional 644,839 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Lucid Diagnostics by 181.5% in the fourth quarter. Renaissance Technologies LLC now owns 826,527 shares of the company’s stock valued at $901,000 after acquiring an additional 532,894 shares during the last quarter. 74.01% of the stock is currently owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.